January 23, 2020
Medwatcher Japan, a citizen’s drug damage watchdog, is nudging the health ministry to withdraw conditional approval granted in 2018 for Nipro’s Stemirac, the first stem cell therapy for spinal cord injury, and reexamine its safety and efficacy in clinical trials...read more